N- cyano- N'- (2- ((8- (2,6- difluorophenyl)- 4- (4- fluoro- 2- methylphenyl)- 7- oxo- 7,8- dihydropyrido(2,3- d)pyrimidin- 2- yl)amino)ethyl)guanidine
Also Known As:
SB 706504; SB-706504; SB706504
Networked: 1
relevant articles (0 outcomes,
0 trials/studies)
Bio-Agent Context: Research Results
Experts
Related Diseases
1. | Chronic Obstructive Pulmonary Disease (COPD)
02/01/2009
- " SB706504 and dexamethasone had no effect on the transcription of a subset of LPS-regulated genes, including IL-1beta, IL-18, and CCL5, which are all known to be involved in the pathogenesis of COPD." 02/01/2009
- " SB706504 significantly inhibited LPS-stimulated TNFalpha production from COPD and smoker AMs, with near-maximal suppression caused by combination treatment with dexamethasone. " 02/01/2009
- " SB706504 caused transcriptional inhibition of a range of cytokines and chemokines in COPD MDMs. " 02/01/2009
- " We have studied the effects of the p38 MAPK inhibitor N-cyano-N'-(2-{[8-(2,6-difluorophenyl)-4-(4-fluoro-2-methylphenyl)-7-oxo-7,8-dihydropyrido[2,3-d]-pyrimidin-2-yl]amino}ethyl)guanidine (SB706504) and dexamethasone on COPD macrophage inflammatory gene expression and protein secretion. " 02/01/2009
- " Inhibition of lipopolysaccharide-stimulated chronic obstructive pulmonary disease macrophage inflammatory gene expression by dexamethasone and the p38 mitogen-activated protein kinase inhibitor N-cyano-N'-(2-{[8-(2,6-difluorophenyl)-4-(4-fluoro-2-methylphenyl)-7-oxo-7,8-dihydropyrido[2,3-d] pyrimidin-2-yl]amino}ethyl)guanidine (SB706504)."
|
|
Related Drugs and Biologics